AI
| Followers | 842 |
| Posts | 122790 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Thursday, November 08, 2007 2:17:09 PM
MNTA’s M118: FIIa vs FXa Binding
This graphic shows why LMWH has less
inhibition of thrombin (FIIa) than of FXa.
LMWH is a complex mixture of variable-length
chains, of which some are capable of binding to
FIIa and some aren’t. Relative to unfractionated
heparin, fewer chains in LMWH are capable of
binding to FIIa and thus LMWH provides
anticoagulation mainly by inhibiting FXa.
M118 from MNTA is a proprietary mixture of
short- and long-chain heparins that is designed
from the ground up to have the binding qualities
and reversibility of unfractionated heparin while
retaining the predictability of response and lack
of monitoring that are the hallmarks of LMWH.
This graphic is best viewed in conjunction with
#msg-23010615, which shows the clotting cascade.
Source of graphic:
http://www.cardiologyrounds.org/crus/crus-12-97.pdf
This graphic shows why LMWH has less
inhibition of thrombin (FIIa) than of FXa.
LMWH is a complex mixture of variable-length
chains, of which some are capable of binding to
FIIa and some aren’t. Relative to unfractionated
heparin, fewer chains in LMWH are capable of
binding to FIIa and thus LMWH provides
anticoagulation mainly by inhibiting FXa.
M118 from MNTA is a proprietary mixture of
short- and long-chain heparins that is designed
from the ground up to have the binding qualities
and reversibility of unfractionated heparin while
retaining the predictability of response and lack
of monitoring that are the hallmarks of LMWH.
This graphic is best viewed in conjunction with
#msg-23010615, which shows the clotting cascade.
Source of graphic:
http://www.cardiologyrounds.org/crus/crus-12-97.pdf
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
